Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1865MR)

This product GTTS-WQ1865MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1865MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8693MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ6902MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5566MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ3820MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ10387MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ14365MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ14354MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ2848MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-570
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW